AstraZeneca (AZNCF) News Today $134.98 +2.85 (+2.16%) As of 01/17/2025 02:55 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendFinancialsHeadlinesOwnershipSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Bank of America Securities Remains a Buy on AstraZeneca (AZN)January 20 at 9:52 PM | markets.businessinsider.comAstraZeneca’s Strong Growth Forecasts and Strategic Position Justify Buy Rating Despite Market ConcernsJanuary 20 at 9:52 PM | markets.businessinsider.comAstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast CancerJanuary 20 at 3:33 AM | markets.businessinsider.comAstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerJanuary 18 at 1:56 AM | msn.comAstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment DatrowayJanuary 17, 2025 | marketwatch.comAstraZeneca overhauls management of its China division, FT reportsJanuary 17, 2025 | msn.comAstraZeneca price target raised to 13,100 GBp from 12,600 GBp at GuggenheimJanuary 17, 2025 | markets.businessinsider.comAstraZeneca overhauls management of its scandal-hit China divisionJanuary 17, 2025 | ft.comAstraZeneca’s Calquence combination approved in U.S.January 17, 2025 | markets.businessinsider.comAstraZeneca's Calquence gets US approval for mantle cell lymphomaJanuary 17, 2025 | lse.co.ukFDA approves AstraZeneca's Calquence for untreated mantle cell lymphomaJanuary 17, 2025 | in.investing.com3 key reasons why AstraZeneca’s share price looks a steal to me right nowJanuary 15, 2025 | uk.finance.yahoo.comAstraZeneca, Daiichi Sankyo datopotamab deruxtecan BLA granted priority reviewJanuary 13, 2025 | markets.businessinsider.comAstraZeneca and Daiichi Sankyo cheer priority US review of cancer drugJanuary 13, 2025 | lse.co.ukDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZenecaJanuary 12, 2025 | markets.businessinsider.comAstraZeneca’s Promising Pipeline and Strategic Initiatives Drive Buy RecommendationJanuary 11, 2025 | markets.businessinsider.comAstraZeneca (AZN) Gets a Buy from J.P. MorganJanuary 6, 2025 | markets.businessinsider.comAstraZeneca (AZN) Reels from China Investigation and Investor Suit- Hagens BermanDecember 30, 2024 | markets.businessinsider.comIs AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?December 29, 2024 | msn.comAstrazeneca (AZN) Stock Moves -0.39%: What You Should KnowDecember 27, 2024 | msn.comAstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five yearsDecember 26, 2024 | finance.yahoo.comWhy Is AstraZeneca PLC (AZN) Among the Best European Dividend Stocks To Buy Now?December 23, 2024 | msn.comROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZNDecember 18, 2024 | markets.businessinsider.comAstraZeneca lacks good medicine for Chinese limboDecember 13, 2024 | reuters.comAstraZeneca (AZN) Gets a Hold from Kepler CapitalDecember 13, 2024 | markets.businessinsider.comAstraZeneca, Daiichi Sankyo announce BTD for datopotamab deruxtecanDecember 9, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)December 9, 2024 | markets.businessinsider.comAstraZeneca granted priority review for Imfinzi sBLADecember 6, 2024 | markets.businessinsider.comDrugmaker AstraZeneca names new China chief to replace detained executiveDecember 6, 2024 | msn.comAZN : TROPION Analysis Reveals Datopotamab Deruxtecan Efficacy In Advanced EGFR-Mutated Lung CancerDecember 6, 2024 | markets.businessinsider.comJ.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)December 3, 2024 | markets.businessinsider.comPharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline SuccessNovember 29, 2024 | msn.comGCAR and AstraZeneca execute agreement to evaluate AZD1390 for glioblastomaNovember 25, 2024 | msn.comAstraZeneca Names A MSK Leader To Global Cancer PostNovember 25, 2024 | forbes.comAstraZeneca PLC ADR underperforms Wednesday when compared to competitorsNovember 20, 2024 | msn.comAstraZeneca Director Invests in Company SharesNovember 20, 2024 | markets.businessinsider.comAstraZeneca shares trade higher on UBS UpgradeNovember 20, 2024 | in.investing.comAstraZeneca raised to neutral at UBS despite China headwindsNovember 20, 2024 | msn.comAstraZeneca upgraded to Neutral from Sell at UBSNovember 20, 2024 | markets.businessinsider.comAstraZeneca price target lowered to EUR 140 from EUR 150 at BerenbergNovember 20, 2024 | markets.businessinsider.comAstraZeneca Loses Lone Bear as UBS Upgrades After China-Led RoutNovember 20, 2024 | bloomberg.comAstraZeneca picks first Treg cell therapy from Quell Therapeutics partnershipNovember 18, 2024 | finance.yahoo.comTOP NEWS: AstraZeneca hails recommended EU approval of TagrissoNovember 18, 2024 | lse.co.ukAstraZeneca’s Tagrisso Gains EU Approval NodNovember 18, 2024 | markets.businessinsider.comAstraZeneca buildings for sale in FairfaxNovember 17, 2024 | warriorswire.usatoday.comAstraZeneca Director Bolsters Stake with Share PurchaseNovember 14, 2024 | markets.businessinsider.comAstraZeneca: Strong Q3 Growth and Strategic Moves Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comAstraZeneca’s Koselugo Expands Potential in Adult TreatmentNovember 13, 2024 | markets.businessinsider.comMerck and AstraZeneca announce results of Koselugo in neurofibromatosis trialNovember 12, 2024 | markets.businessinsider.comAstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'November 12, 2024 | finance.yahoo.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Media Mentions By Week AZNCF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZNCF News Sentiment▼0.370.48▲Average Medical News Sentiment AZNCF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZNCF Articles This Week▼126▲AZNCF Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today American Premium Mining News Today Anew Medical News Today Arno Therapeutics News Today AVAX Technologies News Today AVVAA World Health Care Products News Today AXIM Biotechnologies News Today biote News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AZNCF) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AZNCF Stock Alerts